719 Phase 1 clinical trial design of ZM008, a first-in-class anti LLT1 antibody is a promising therapy for multiple solid cancers

• Ignacio Garcia-Ribas,
• Maloy Ghosh,
• Anurag Tiwari,
• Sanghamitra Bhattacharjee,
• Yogendra Manjunath,
• Shalini Kashipathi,
• Subith Krishna,
• Ashvini Kumar Dubey,
• Tirtha Mandal,
• Soorya Gnanasegaran

Affiliations

Ignacio Garcia-Ribas

Imperial Cancer Research Fund/Richard Dimbleby Department of Cancer Research, St Thomas`s Hospital, London SE1 7EH

Maloy Ghosh

Zumutor Biologics, Bangalore, India

Anurag Tiwari

Zumutor Biologics, Bangalore, India

Sanghamitra Bhattacharjee

Zumutor Biologics Pvt Ltd, Bangalore, India

Yogendra Manjunath

Zumutor Biologics, Bangalore, India

Shalini Kashipathi

Zumutor Biologics, Bangalore, India

Subith Krishna

Zumutor Biologics, Bangalore, India

Ashvini Kumar Dubey

Zumutor Biologics Pvt Ltd, Bangalore, India

Tirtha Mandal

Zumutor Biologics Pvt Ltd, Bangalore, India

Soorya Gnanasegaran

Zumutor Biologics Pvt Ltd, Bangalore, India